Its expression is activated in 93% of HL cases (41) and the mTOR inhibitor Everolimus is considered an antiproliferative agent as well as targeted treatment for refractory/relapsed HL (2), while a combination of Akt and mTOR inhibitors can be effectively treated in non-Hodgkin lymphomas (42). This evidence concerns the gene AKT1 and Hodgkins lymphoma.